Head-To-Head Comparison: Jaguar Animal Health (JAGX) versus Its Peers

Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Jaguar Animal Health to similar businesses based on the strength of its valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Profitability

This table compares Jaguar Animal Health and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jaguar Animal Health -187.88% N/A -131.45%
Jaguar Animal Health Competitors -2,398.26% -203.62% -15.08%

Earnings & Valuation

This table compares Jaguar Animal Health and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Jaguar Animal Health $11.51 million -$53.43 million -0.00
Jaguar Animal Health Competitors $18.73 billion $3.24 billion 559.25

Jaguar Animal Health’s peers have higher revenue and earnings than Jaguar Animal Health. Jaguar Animal Health is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Jaguar Animal Health has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500. Comparatively, Jaguar Animal Health’s peers have a beta of -0.04, indicating that their average share price is 104% less volatile than the S&P 500.

Insider & Institutional Ownership

12.0% of Jaguar Animal Health shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.1% of Jaguar Animal Health shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Jaguar Animal Health and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jaguar Animal Health 1 0 0 0 1.00
Jaguar Animal Health Competitors 7845 13798 25818 1039 2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.20%. Given Jaguar Animal Health’s peers stronger consensus rating and higher possible upside, analysts plainly believe Jaguar Animal Health has less favorable growth aspects than its peers.

Summary

Jaguar Animal Health peers beat Jaguar Animal Health on 11 of the 13 factors compared.

About Jaguar Animal Health

(Get Free Report)

Jaguar Health, Inc., formerly Jaguar Animal Health, develops prescription medicines for gastrointestinal disorders in humans and animals. The company’s research has focused on plant-derived compounds, including crofelemer, which is derived from the Croton lechleri tree. Jaguar’s animal-health product Canalevia-CA1 received FDA conditional approval for the treatment of chemotherapy-induced diarrhea in dogs. The company also develops and commercializes crofelemer-based medicines for human gastrointestinal conditions.

Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.